Related Experiment Video
Updated: Aug 18, 2026
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better?
1Division of Clinical Neurology, Faculty of Medicine, University Hospital, Queen's Medical Centre, Nottingham, UK.
Abstract:
Published Phase III immunomodulatory treatment trials in relapsing and remitting multiple sclerosis have demonstrated a modest decline in attack rates, but only a minor effect on disability. As genuine disability progression is difficult to ascertain in relatively short studies with the conventional rating scales available, the acquisition and analysis of relapse data are critical. However, there are as yet unresolved questions related to the latter. We will first discuss the problems associated with relapse definitions by trial investigators, the paucity of the data collected (especially on the magnitude and duration of exacerbations) and statistical issues in their analysis. We will then suggest practical points for obtaining more accurate information on relapses and evaluating them meaningfully. While there is still general consensus among neurologists that primary endpoints for therapeutic trials should be clinical, improvements for future protocols are essential.
Insights
Multiple sclerosis clinical trials show limited impact on disability progression. Improving relapse data collection and analysis is crucial for accurately assessing immunomodulatory treatments in multiple sclerosis research.
Area of Science:
- Neurology
- Clinical Trials
- Immunomodulatory Therapies
Background:
- Phase III trials for relapsing-remitting multiple sclerosis (RRMS) using immunomodulatory treatments show modest reductions in attack rates.
- These treatments have demonstrated only a minor effect on overall disability progression in RRMS patients.
Purpose of the Study:
- To address challenges in accurately assessing disability progression in multiple sclerosis (MS) trials.
- To highlight issues in relapse data acquisition and statistical analysis for MS clinical trials.
- To propose improvements for future MS therapeutic trial protocols.
Main Methods:
- Discussion of problems in relapse definitions by trial investigators.
- Analysis of data paucity, particularly regarding the magnitude and duration of exacerbations.
- Examination of statistical challenges in analyzing relapse data.
Main Results:
- Current rating scales and short study durations hinder accurate assessment of genuine disability progression in MS.
- Existing relapse data collection and analysis methods present significant unresolved questions.
- Immunomodulatory treatments offer limited benefits for disability in MS.
Conclusions:
- Accurate acquisition and meaningful evaluation of relapse data are critical for MS clinical trials.
- Improvements in relapse definitions, data collection (magnitude, duration), and statistical analysis are essential.
- While clinical endpoints remain standard, future MS trial protocols require enhancement.
